Skip to content

Clinical trial of comparison of effectiveness of Omega-3 supplement on PCOS and metabolic syndrome with placebo

Comparison of effectiveness of Omega3 supplementation on poly cystic ovary syndrome(PCOs) symptoms and metabolic syndrome according of the NIH criteria

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201604193924N3
Enrollment
88
Registered
2017-03-10
Start date
2016-05-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Polycystic ovarian syndrome. Condition 2: menstural disorder. Condition 3: metabolic syndrom. Condition 4: hyperandrogenism. Condition 5: hirsutism. Sclerocystic ovary syndrome Stein-Leventhal syndrome hypomenorrea Nos, bleeding NOs, periods NOS metabolic disorder unspecified hyper secretion of ovarian androgen genital hair exess in female

Interventions

Intervention 1: intervention group : gives Omega 3 supplementation for 6 mounts. Intervention 2: control group : gives 2 placebo capsule daily for 6 mounts.
Treatment - Drugs
intervention group : gives Omega 3 supplementation for 6 mounts.
control group : gives 2 placebo capsule daily for 6 mounts

Sponsors

Vice chancllor for Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: Patients who have informed consent ; PCOS disease, according to the NIH3 ; age between 18-40 ; Exclusion criteria: smoking, use of oral pregnancy pill or alcohol or fish oil in 3 month ago or into the study ; pregnancy; have disease of kidney or liver or heart or thyroid ; diabetes ; hyperprolactinemia ; Cushing, Adrenal congenital hyperplasia, menopause ; the patient withdrew into the study ; Failure to follow the next visit

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Menstrual disorders. Timepoint: 6 mounth afther implementation study. Method of measurement: questionnaire of Bleeding volume, number of days of spotting, Menstrual periods.;Body mass index. Timepoint: 6 mounth afther implementation study. Method of measurement: Weight in kilograms divided by the square of height in meters.;Hirsutism. Timepoint: 6 mounth afther implementation study. Method of measurement: Ferrimen- Gullway score.

Secondary

MeasureTime frame
Abdominal circumference. Timepoint: and 6 mounths after implemention of study. Method of measurement: The size of the margin around the narrowest part of the lower ribs and the iliac crest at the end of a normal exhalation.;Hip circumference. Timepoint: 6 mounths after implemention of study. Method of measurement: Hip circumference on the line that connects the two greater trochanter.;Fasting blood sugare. Timepoint: 6 mounths after implemention of study. Method of measurement: blood glucose levels after 8 hours fasting.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Sajedhe Jafari

Isfahan University of Medical Siencese

hb32us@yahoo.com+98 913 368 1360

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026